Literature DB >> 15700728

The clinical use of the MSLT and MWT.

Donna Arand1, Michael Bonnet, Thomas Hurwitz, Merrill Mitler, Roger Rosa, R Bart Sangal.   

Abstract

The studies examined in this review indicate that the MSL is sensitive to conditions expected to increase sleepiness. MSL are generally lower following sleep loss, following use of sedating medications, during wakefulness in the late night or early morning hours, and among patients with sleep disorders associated with excessive sleepiness such as narcolepsy or obstructive sleep apnea. However, the wide range in MSL makes it difficult to establish a specific threshold value for excessive sleepiness or to discriminate patients with sleep disorders from non-patients. Some of this variation may be attributable to methodological differences and some may be attributable to individual differences in sleep tendency (e.g., related to age). The studies analyzed in this review indicate that the MSL on both the MSLT and MWT does not discriminate well between patients with sleep disorders and normal populations. This is due to large SD as well as floor or ceiling effects in the tests. However, the MSL shows appropriate change from initial testing to subsequent testing following treatment or manipulations intended to alter sleepiness or alertness. Additionally the presence of two or more SOREMPs on the MSLT is a common finding in narcolepsy patients. However, SOREMPs are not exclusive to narcolepsy patients but are frequent in untreated sleep apnea

Entities:  

Mesh:

Year:  2005        PMID: 15700728     DOI: 10.1093/sleep/28.1.123

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  64 in total

1.  The assessment, diagnosis, and treatment of excessive sleepiness: practical considerations for the psychiatrist.

Authors:  Dewey McWhirter; Charles Bae; Kumaraswamy Budur
Journal:  Psychiatry (Edgmont)       Date:  2007-09

2.  Reliability of a single objective measure in assessing sleepiness.

Authors:  Bernie Y Sunwoo; Nicholas Jackson; Greg Maislin; Indira Gurubhagavatula; Charles F George; Allan I Pack
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

3.  The 10-year risk of verified motor vehicle crashes in relation to physiologic sleepiness.

Authors:  Christopher Drake; Timothy Roehrs; Naomi Breslau; Eric Johnson; Catherine Jefferson; Holly Scofield; Thomas Roth
Journal:  Sleep       Date:  2010-06       Impact factor: 5.849

Review 4.  Vigilance, alertness, or sustained attention: physiological basis and measurement.

Authors:  B S Oken; M C Salinsky; S M Elsas
Journal:  Clin Neurophysiol       Date:  2006-04-03       Impact factor: 3.708

5.  Measuring the ability to stay awake: role of motivation.

Authors:  James A Rowley
Journal:  Sleep Breath       Date:  2006-12       Impact factor: 2.816

6.  How much prior sleep is adequate for the multiple sleep latency test?

Authors:  Donna Arand
Journal:  J Clin Sleep Med       Date:  2007-10-15       Impact factor: 4.062

7.  Forty- versus 20-minute trials of the maintenance of wakefulness test regimen for licensing of drivers.

Authors:  Limor Arzi; Roni Shreter; Baruch El-Ad; Ron Peled; Giora Pillar
Journal:  J Clin Sleep Med       Date:  2009-02-15       Impact factor: 4.062

8.  Nightly sleep duration in the 2-week period preceding multiple sleep latency testing.

Authors:  David A Bradshaw; Matthew A Yanagi; Edward S Pak; Terry S Peery; Gregory A Ruff
Journal:  J Clin Sleep Med       Date:  2007-10-15       Impact factor: 4.062

9.  Daytime sleepiness and driving performance in patients with obstructive sleep apnea: comparison of the MSLT, the MWT, and a simulated driving task.

Authors:  Fabio Pizza; Sara Contardi; Susanna Mondini; Lino Trentin; Fabio Cirignotta
Journal:  Sleep       Date:  2009-03       Impact factor: 5.849

10.  Evaluating sleepiness-related daytime function by querying wakefulness inability and fatigue: Sleepiness-Wakefulness Inability and Fatigue Test (SWIFT).

Authors:  R Bart Sangal
Journal:  J Clin Sleep Med       Date:  2012-12-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.